Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 668 across all filing types
Latest filing 2024-11-19 Director's Dealing
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-11-19 English
4
Director's Dealing
2024-11-19 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Seres Therapeutics, Inc. It includes multiple items: Item 2.02 reports the announcement of quarterly financial results for the quarter ended September 30, 2024, with the full press release attached as Exhibit 99.1; Item 3.01 is a notice of delisting risk due to the stock price falling below Nasdaq's minimum bid price requirement; Item 7.01 discloses an updated corporate presentation attached as Exhibit 99.2. The document is not the earnings release itself but a regulatory filing that furnishes the press release and presentation as exhibits. The text explicitly states that the exhibits are "furnished, and not filed," and the information is not deemed "filed" for purposes of Section 18 of the Exchange Act. The document is about reporting events and disclosures rather than containing substantive financial statements or detailed financial analysis. The delisting notice is a key feature, which is a formal announcement about potential removal from the exchange. Given the combination of a delisting notice and the furnishing of a press release and presentation, the primary classification is a Regulatory Filing (RNS) because it does not contain the full earnings release or financial report itself but reports on multiple regulatory matters including delisting risk and operational updates. The document length (9464 characters) and content support this classification rather than a pure Earnings Release or Delisting Announcement alone, as it includes multiple items and is a formal SEC filing form 8-K.
2024-11-13 English
4
Director's Dealing
2024-10-29 English
4
Director's Dealing
2024-10-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.